Survival prolongation by adding local chemotherapy in reoperated on GBM patients

A. Silvani, A. Pozzi, A. Salmaggi, G. Broggi, A. Boiardi

Research output: Contribution to journalArticlepeer-review


We scheduled a protocol by combining both local bleomycina and mitoxantrone in addition to systemic chemotherapy in 54 primary GBM selected pts. according to our eligibility requirements. Moreover 15 out of them underwent a second surgery. 1)BCNU 100mg/m2 + CDDP 90 mg/m2 I.V. for 5 times 2) bleomicin 0,75 mg in 2 cc of phisyological solution days 1-2-3 and mitoxantrone 3 mg day 4 trough Ommaya every 20 days.3) At recurrence PVC every 6 weeks Drugs interstitially delivered by-pass the bloodbrain-barrier and can achieve higher and more prolonged concentrations. There was no evidence of increased brain toxicity from the local delivery of bleomycin and mitoxantrone. The whole group of pts.(54), those treated with locoregional chemotherapy ( 25) and 15 pts reoperated on had 23.1; 26,5 and 27,6 mos ST respectively. Our present findings emphasize the safety and effectiveness of locoregional chemotherapy as noted in the literature. The uncertety remains that temporary stabilization of disease may reflect the natural history of the disease as well as therapeutic effects.Extensive surgery could be justifiable if it is a part of the whole program of treatment We feel confident that the addition of intratumoral chemotherapy was effective and was a determining factor in association with a secod tumor resection in the prolongation of ST in our selected patients.

Original languageEnglish
Pages (from-to)143
Number of pages1
JournalItalian Journal of Neurological Sciences
Issue number4
Publication statusPublished - 1997

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology


Dive into the research topics of 'Survival prolongation by adding local chemotherapy in reoperated on GBM patients'. Together they form a unique fingerprint.

Cite this